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robust in the one-way sensibility analyses and the probabilistic sensitivity analy-
sis indicating that the absence of monitoring strategy has the highest probability 
of cost-effectiveness ConClusions: Long-run WBC monitoring based on current 
national detection guidelines is not cost-effective, even by unrealistically high 
agranulocytosis prevalence. New guidelines are needed to improve WBC monitor-
ing in schizophrenic patients receiving Clozapine.
PSY2
OSteOtOmia De acOrtamientO raDial en la enfermeDaD De KienbOcK 
(SeguimientO De 5 añOS)
Vazquez Alonso F.
imss hospital de traumatologia y ortopedia lomas verdes, naucalpa edo de mexico, Mexico
objeCtivos: evaluar los resultados clinicos y funcionales ( grado de satisfacción 
) de paciente con enfermedad de kienbock ttratados con osteotomia de acor-
tamiento radial. MetodologíAs: estudio realizado en la umae de traumato-
logia y ortopedia lomas verdes del imss, en el servicio de cirugia de mano, en 
un periodo comprendido entre 2000 al 2003, con seguimiento de 5 años.estudio 
retrospectivo, observacional, transversal. se estudiaron ´18 pacientes de ambos 
sexos con diagnostico de enfermedad de kienbock utilizando la clasificacion de 
litchman, evaluados con las escala de wrist mayo score y QDash. pba estadistica 
de wiscolson ResultAdos: se obtuviero 18 paciente 9 mujeres y 9 hombres, el 
84% obreros 16% al hogar, de acuerdo al resultados de la escla funcional wrist 
mayo score fueron 56% buenos, 33% excelentes, 5.5% malo, 5% regulares, con 25 
puntos de grado de satifaccion de acuerdo al QDash. un paciente fue reinterve-
nido 2 años posteriores al cual se le realizo una artrodesis delas cuatro esqui-
nas. ConClusiones: la evaluacion clinica y funcional, sugiere una eficacia 
aceptable de la osteotomia de acortamiento radial y provee datos alentadorespara 
continuar con este tipo de tratamiento.
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the relatiOnShiP between SPecific annual bleeD rateS anD health 
OutcOmeS amOng chilDren with Severe hemOPhilia a in latin 
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objeCtives: Recurrent bleeding among severe hemophilia A children can lead to 
disability and lower health-related quality of life (HRQOL). Little is known about 
how many bleeds can be endured before patients report an impact on health 
outcomes. The objective was to assess health outcomes of pediatric patients 
reporting a zero annual bleed rate (ABR) to identify the impact of higher ABRs on 
outcomes. Methods: This cross-sectional survey of parents of severe hemophilia 
A patients aged 2-17 was conducted in Argentina, Chile, Colombia, Mexico and 
Panama. Eligible, consenting patients completed a questionnaire: from October-
November 2009 (Argentina), June-August 2011 (Chile, Colombia, Mexico) and 
September-October 2012 (Panama). HRQOL was measured by the Pediatric Quality 
of Life Inventory (PedsQL). ABR, target joints and school days missed were also 
assessed. Results: A total of 211 parents of severe hemophilia A children com-
pleted the survey. Compared to patients with a 0 ABR who reported a mean PedsQL 
Total score of 76.6, patients with ABR categories of: 3-4, 5-10, 11-20, 21-30, 31-50, 51 
or more showed significantly worse mean PedsQL Total scores of: 66.4, 63.5, 67.4, 
62.5, 62.4 and 59.9 respectively (all p< 0.05). Similarly, compared to patients with 0 
ABR who reported a mean number of target joints of 0.69, patients with higher ABR 
categories showed significantly higher mean target joints: 1.49, 2.57, 3.42, 3.47, 3.74, 
4.67 (all p< .05). Differences in missed days from school showed the same significant 
trend when comparing 0 ABR to ABR categories of 3-4 and beyond. There were no 
significant differences between patients with zero compared to 1-2 ABR on these 
health outcomes. ConClusions: This analysis suggests that even 3-4 bleeds/year 
may have a negative impact on a patient’s joint health, missed school days and 
HRQOL. Efforts to maintain a 0 ABR among pediatric patients with severe hemophilia 
A may help ensure optimal outcomes.
PSY4
efficacY anD SafetY Of belimumab fOr the treatment Of SYStemic 
luPuS erYthematOSuS
Borba H.H.L., Wiens A., Correr C.J., Pontarolo R.
Universidade Federal do Paraná, Curitiba, Brazil
objeCtives: To evaluate the efficacy, safety and tolerability of 1 and 10 mg/kg beli-
mumab, a biologic drug, for the treatment of Systemic Lupus Erythematosus (SLE) 
through a meta-analysis, comparing these treatments with placebo. Methods: A 
systematic review and meta-analysis of randomized, placebo-controlled trials of beli-
mumab was conducted. Data were collected from several databases until August 2012. 
Efficacy outcomes included the SELENA-SLEDAI score (Safety of Estrogens in Lupus 
Erythematosus National Assessment version of the SLE Disease Activity Index), SRI 
(Systemic Lupus Erythematosus Responder Index), normalization of low C3 (< 90 mg/
kg), and anti-dsDNA positive to negative. Data on safety included any adverse events, 
serious adverse events, severe adverse events, death, malignancy, infections, and infu-
sion reactions. We also evaluated withdrawals from treatment due to lack of efficacy 
or adverse events. Results: Fours studies were included in this study. Anti-dsDNA 
positive to negative was the most significant efficacy outcome in our meta-analysis for 
both of the evaluated concentrations. No significant differences in the safety data were 
observed between the belimumab (1 and 10 mg/kg) and placebo groups. Tolerability 
results revealed no significant differences in withdrawals due to lack of efficacy 
and adverse events between the belimumab and placebo groups. ConClusions: 
Belimumab exhibited good efficacy results, especially at 10 mg/kg, a good safety profile, 
and adequate tolerability, which indicates that this biologic drug is a promising therapy 
PrS14
level Of aSthma cOntrOl anD health care utilizatiOn in latin 
america
Montealegre-Golcher F.1, Gold L.2, Allen-Ramey F.3, Jardim J.R.4, Sansores Martinez R.H.5, 
Sullivan S.2
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objeCtives: Data on the impact of asthma in Latin American countries is limited. 
The purpose of this study was to examine the association between partly- and 
uncontrolled asthma and asthma-related health care outcomes among patients 
residing in Argentina, Brazil, Mexico, Venezuela and the Common wealth of Puerto 
Rico. Methods: Adults and parents of adolescents (12-17 years) with physician 
diagnosed asthma and asthma medication use or asthma attacks in the past year 
were surveyed as part of the 2011 Latin America Asthma Insights and Management 
(AIM) survey. Using Global Initiative for Asthma (GINA) guidelines as a reference, 
respondents were categorized into three levels of asthma control: well-controlled, 
partly- controlled, and uncontrolled. Chi-square tests and adjusted logistic regres-
sion were used to determine odds ratios (ORs) to assess the relation of degree of 
asthma control with utilization of asthma medications, health care outcomes, and 
productivity. Results: Data was available for 2169 completed surveys. Overall, 
7% of the patients surveyed had asthma that was classified as well-controlled, 
with the highest proportion in Mexico (9.4%) and the lowest in Venezuela (3.0%). 
Patients whose asthma was not well-controlled were significantly more likely to 
report use of asthma medications (ORs ranging from 1.5-42) and to have had emer-
gency health care visits or hospitalizations for their asthma in the previous year 
(ORs ranging from 2.1-5.9). Respondents with uncontrolled asthma also reported 
significant decreases in productivity due to asthma compared to patients with 
well-controlled asthma. ConClusions: Patients who did not have well-controlled 
asthma had greater utilization rates of asthma medications and emergency health 
care services compared to patients whose asthma was well-controlled. These asso-
ciations strongly suggest that emphasis on improving asthma control could have 
substantial effects on patient productivity and utilization of health care resources.
PrS15
caracteríSticaS SOciOecOnómicaS De PacienteS cOn enfermeDaD 
vaScular cerebral Y anteceDenteS De tabaquiSmO trataDOS en un 
hOSPital De tercer nivel De méxicO
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Aguirre-Cruz L.4
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objeCtivos: Determinar las variables socioeconómicas asociadas a pacientes con 
enfermedad vascular cerebral (EVC) y antecedentes de tabaquismo, tratados en 
un centro neurológico de tercer nivel en México. MetodologíAs: Es un estudio 
cuantitativo, descriptivo, transversal y retrospectivo. Los pacientes debían tener 
edades ≥ 35 años, antecedentes de tabaquismo y diagnóstico de EVC; clasificados 
por el sistema CIE-10 (I60-I69). Se revisaron 174 expedientes del 2011. Se utilizó el 
análisis de componentes principales para estimar los pesos de las variables socioec-
onómicas. La adecuación del modelo se realizó mediante la medida de Kaiser-Meyer-
Oklin (KMO), la prueba de Bartlett y la consistencia interna mediante el alpha de 
Crombach (α ). ResultAdos: De los 174 pacientes 78(45%) presentaron antecedentes 
de tabaquismo y de estos 49(63%) fueron hombres, con 58±14 (media, DE) años de 
edad y 9.4±5.3 de escolaridad, nivel socioeconómico de 2.3±1.1, 71(91%) habita en 
departamentos populares y 37(47%) se dedicaron al hogar o fueron trabajadores no 
calificados. Se obtuvo un α = 0.80, KMO= 0.78 y Bartlett (p= 0.000). Dos componentes 
explicaron 58.3% de la varianza total. El primero; (42.02%), se integró por las vari-
ables servicio intra-domiciliario (Ponderación;0.763), estatus socioeconómico (0.749), 
escolaridad (0.748), zona de ubicación (0.673), material de construcción (0.707), ubi-
cación de la vivienda (0.673) y ocupación (0.437). el segundo; (16.24%), con el tipo de 
vivienda (0.564) y número de habitaciones (0.460). ConClusiones: Los pacientes 
atendidos por EVC se caracterizaron por niveles bajos de escolaridad y clasificación 
socioeconómica, ocupaciones poco remunerables y edad avanzada; que los hace 
vulnerables a la enfermedad.
SYStemic DiSOrDerS/cOnDitiOnS – clinical Outcomes Studies
PSY1
agranulOcYtOSiS DetectiOn OutcOme bY clOzaPine treatment (aDOc 
StuDY) in PSYchiatrY: a cOSt-effectiveneSS StuDY
Girardin F., Poncet A., Blondon M., Vernaz N., Combescure C.
University of Geneva Hospitals, Geneva, Switzerland
objeCtives: White Blood Cell (WBC) monitoring in schizophrenic patients treated 
by Clozapine aims to prevent agranulocytosis. We assess the cost-effectiveness of 
WBC monitoring strategies based on three national regulations and an additional 
weekly short-run monitoring compared to the absence of monitoring. Methods: 
A decision analytic model was built to perform a cost-utility analysis comparing 
distinct monitoring strategies from a health care perspective with a 3-year time 
horizon. Clinical and resources used parameters were based on national Clozapine 
patients’ registries, cohorts, and pharmacovigilance data; health-related quality 
of life and mortality estimates were derived from literature reviews. Robustness 
of results was challenged with one-way and probabilistic sensitivity analy-
ses. Results: Compared to the absence of monitoring, the number needed to treat 
of all strategies to avoid one death was 5,000. The gains in survival time adjusted 
on quality of life were less than 1 day, resulting in prohibitive incremental cost-
effectiveness ratios (ICER) of at least 1 million USD per QALY gained,. The ICER 
increased with higher frequency and longer monitoring duration. The results remain 
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hibidores, el costo promedio por paciente/mes en demanda es de $ 26,427,616 y el 
costo promedio paciente/mes en profilaxis secundaria es de $ 23,032,817 (p= 0,456). 
Sin contabilizar los medicamentos antinhibidores el costo promedio por paciente/
mes en demanda es de $ 4,143,308 y el costo promedio paciente/mes en profilaxis 
secundaria es de $ 19,113,948 (p< 0,0001). ConClusiones: No se observa diferen-
cia significativa en la tasa de sangrados en los grupos de profilaxis secundaria y 
demanda. El grupo de pacientes con inhibidores experimenta el mayor costo dentro 
de la población observada. Al excluir los inhibidores el costo promedio/paciente/mes 
en profilaxis secundaria es 4,6 veces mayor que el costo en tratamiento a demanda.
PSY8
biOlOgical agentS in the treatment Of mODerate tO Severe PSOriaSiS: 
a PharmacOecOnOmic analYSiS
Riveros B.S., Souza T.T., Godoy R.R., Garcia M., Gonçalves P., Rotta I., Otuki M.F., Pontarolo R., 
Correr C.J.
Universidade Federal do Paraná, Curitiba, Brazil
objeCtives: To evaluate the cost-effectiveness of biologic agents in the treatment 
of moderate to severe psoriasis. Methods: Four biologics were assessed: adali-
mumab, etanercept, infliximab and ustekinumab. Direct costs were obtained from 
the perspective of Brazilian Public Health Service (SUS). Probabilities and efficacy 
were extrapolated from literature. Unit costs is the Brazilian currency – Real (R$) 
– and the outcomes considered were PASI90 and PASI75 response (rPASI90 and 
rPASI75, respectively). For each outcome one Markov Model was created with 12 
cycles of 3 months (3 years). Annual discounting of 5% was applied for costs and 
outcomes. The model considered patients with moderate to severe psoriasis who 
had Psoriasis Severity Index or Dermatology Quality of Life Index greater than 10 or were 
unable to take standard systemic therapies. Univariate and probabilistic sensitivity 
analysis was applied to evaluate parametric uncertainties. Results: Results were 
expressed as the financial resources demanded for each patient that have achieved 
and kept rPASI90 or rPASI75. Regarding rPASI90, adalimumab showed to be domi-
nant against the other biologics with a total cost of R$ 64,588.79 (U$ 32,714.78) and 
33,7% of patients with rPASI90 after 3 years of treatment (R$ 191,658.13/rPASI90, U$ 
97,076.50/rPASI90). When rPASI75 is considered as the measure of outcome, adali-
mumab and ustekinumab were dominant against infliximab and etanercept, with R$ 
124,200.41/rPASI75 (U$ 62,908.58/rPASI75) and R$ 114,230.59/rPASI75 (U$ 57,858.78/
rPASI75), respectively. Univariate sensitivity analysis pointed acquisition cost of bio-
logics as the main critical variable. Probabilistic sensitivity analysis shows robust-
ness of our findings. ConClusions: From the perspective of SUS, adalimumab is 
the most cost-effective biological agent for rPASI90. Threshold up to R$ 124,000/
rPASI75 (U$ 62,807.07/rPASI75) favors ustekinumab as the most cost-effective drug, 
while threshold greater than that point to adalimumab. Is being conducted a new 
Markov modelling to evaluate which sequence of biologic agents is the most cost-
effective when failure of initial biological treatment occurs.
PSY9
a cOSt-effectiveneSS mODel cOmParing Sub-cutaneOuS biOlOgic 
treatment fOr Severe Plaque PSOriaSiS in mexicO
Valencia A.1, Hernandez A.1, Puig A.2
1Janssen, Mexico City, Mexico, 2Johnson and Johnson World Headquarters, New Brunswick, NJ, 
USA
objeCtives: To evaluate the cost-effectiveness of different sub-cutaneous bio-
logic treatments for severe plaque psoriatic patients in public institutions in 
Mexico. Methods: A Markov model was developed to simulate patients with 
moderate-to-severe plaque psoriasis. Biologic therapies compared were usteki-
numab 45mg every 12 weeks, adalimumab 40mg every two weeks, and etanercept 
50mg twice a week. Measured by the Psoriasis Area and Severity Index (PASI), clinical 
response was derived from the latest published meta-analysis. PASI response was 
translated into QALYs in two steps: (1) defining the correlation between PASI levels 
and the Dermatology Life Quality Index (DLQI); and (2) using a formula to predict 
utility from DLQI score derived from a mapping exercise of the DLQI with the EQ-5D. 
The model considered expenditure on drugs, monitoring visits, adverse events and 
inpatient stays. Costs were obtained from Mexican public institutions. Health and 
economic outcomes were estimated over a 10-year time horizon with cycle length 
of 12 weeks. Cost and QALYs were discounted at 5% annually. Results: Etanercept 
is the least costly treatment in Mexican public institutions followed closely by adali-
mumab and ustekinumab. Cost-effectiveness analysis shows that adalimumab was 
an extended dominated strategy by ustekinumab. The incremental cost-per-QALY 
of ustekinumab versus etanercept was US$19,542. ConClusions: Considering the 
GDP per-capita of Mexico in 2010 (US$9,123), and according to the WHO Commission 
on Macroeconomics and Health, ustekinumab is a cost-effective strategy (≤ 3xGDP 
per-capita /QALY gained) versus etanercept, and a more cost-effective strategy vs 
adalimumab by extended dominance. Probabilistic sensitivity analysis results did 
not change the conclusions.
PSY10
análiSiS cOStO-efectiviDaD Del tratamientO farmacOlógicO Para 
laS manifeStaciOneS clínicaS mucOcutáneaS De la enfermeDaD De 
behcet
Quirland Lazo C.
Universidad de Chile, Santiago, Chile
objeCtivos: Determinar la efectividad de la intervenciones farmacológicas dis-
ponibles en Chile para tratar las manifestaciones clínicas de tipo mucocutáneas, 
esto es úlceras orales (UO) y genitales (UG), en la Enfermedad de Behcet (EB). 
Conducir un análisis de costo-efectividad para determinar la alternativa superior 
entre los dos tratamientos que resulten más efectivos. MetodologíAs: Se efectuó 
una revisión de la literatura de los trabajos publicados entre 1980-2010, disponibles 
en las bases de dados MEDLINE y Cochrane Library. Se incluyeron en los criterios 
de selección todos los estudios clínicos controlados, aleatorizados, además de revi-
siones sistemáticas y meta-análisis disponibles bajo las palabras claves enfermedad 
for the treatment of SLE. Additional randomized placebo-controlled trials should be 
conducted to establish the efficacy and safety of belimumab.
SYStemic DiSOrDerS/cOnDitiOnS – cost Studies
PSY5
imPactO financierO Del tratamientO farmacOlógicO en PacienteS 
aDultOS cOn enfermeDaD De gaucher tiPO 1 en méxicO
Soto-Molina H.1, Pizarro M.2, Huicochea-Bartelt J.L.3, Rubio-Borja M.E.3, Muciño-Ortega E.3, 
Galindo-Suárez R.M.3
1Comercializadora Iteliness S.A. de C.V., Ciudad de México, Mexico, 2Hospital Infantil de Mexico 
Federico Gomez, México D.F., Mexico, 3Pfizer S.A. de C.V., Ciudad de México, Mexico
objeCtivos: La enfermedad de Gaucher (EG) es una enfermedad de baja preva-
lencia caracterizada por deficiencia de la enzima glucocerebrosidasa ácida, que 
promueve la acumulación del sustrato glucocerebrósido en lisosomas de monocitos-
macrófagos, lo que conduce a hipertrofia del sistema lisosomal celular, infiltrando 
tejido esquelético, medula ósea, bazo, hígado, pulmones y cerebro, causando dis-
función orgánica. El uso de la terapia de remplazo enzimático (TRE) revierte la orga-
nomegalia, previene complicaciones e incrementa la calidad de vida. El propósito 
del estudio fue evaluar el impacto económico de la TRE en pacientes con EG tipo 
1 desde la perspectiva institucional Mexicana. MetodologíAs: La prevalencia 
en México de pacientes con EG se extrajo de fuentes publicadas. Se estimaron los 
costos promedio del tratamiento de las TRE disponibles en México en pacientes 
de alto riesgo (60UI/Kg cada 2 semanas durante 6 meses, posteriormente 30UI/
Kg durante 6 meses) y de bajo riesgo (30UI/Kg cada 2 semanas durante 6 meses, 
posteriormente 20UI/Kg durante 6 meses). Los costos de adquisición de las TRE se 
extrajeron de fuentes gubernamentales y se expresan en US$ de 2012. Se estimó el 
impacto presupuestal del uso de TRE a nivel institucional en base al Presupuesto de 
Egresos de la Federación (2012). ResultAdos: El número de pacientes con EG tipo 
1 fue de 22 para bajo riesgo y 8 para alto riesgo. El costo promedio anual de la TRE 
por paciente de bajo riesgo fue de US$153,265, para pacientes de alto riesgo fue de 
$260,551, un 70% más. La carga financiera para las instituciones de salud pública 
fue aproximadamente US$338,000 para pacientes de bajo riesgo y US$575,000 para 
pacientes de alto riesgo, lo que agregado representa el 0.016% del gasto público en 
salud de México. ConClusiones: La estimación del impacto presupuestal de la TRE 
en México es relevante para la planeación de los recursos financieros necesarios.
PSY6
análiSiS De la carga financiera De laS PrinciPaleS enfermeDaDeS 
reumatOlógicaS
Goycochea M.1, García O.1, Peláez I.1, Tobón U.1, Julian F.1, Rodriguez Mendoza M.M.2, Soto H.3
1Hospital Regional de Alta Especialidad Oaxaca, Oaxaca, Mexico, 2Universidad Autónoma 
Metropolitana, Distrito Federal, Mexico, 3Health Solutions Consulting, D. F., Mexico
objeCtivos: Realizar un análisis de la carga financiera desde la perspectiva del 
paciente de las principales enfermedades reumatológicas y qué impacto tiene en el gasto 
de las familias en el estado de Oaxaca, México. MetodologíAs: Se evaluó el gasto 
catastrófico de las enfermedades reumáticas. En 2011 se encuestó a nueve pacientes 
diagnosticados con enfermedades reumatológicas del hospital de especialidades de la 
SSA y hospitales privados (tres de artritis reumatoide (AR), cuatro de Lupus eritomatoso 
sistémico (LES), uno de Dermatomiositis y uno de Espondilitis Anquilosante (EA)). El 
instrumento de recolección de datos se centró en la carga financiera del manejo de la 
enfermedad. Se evaluaron los costos médicos directos (fisioterapia, estudios de labora-
torio y tratamiento farmacológico), intervenciones quirúrgicas y costos de transporte. 
Se estimó el costo anual del tratamiento con rituximab (2 infusiones de 1000mg por año) 
y qué impacto representaría para el ingreso familiar. ResultAdos: El costo médico 
promedio anual ascendió a $43,271.00, el costo promedio anual con gasto en transporte 
ascendió a $55,537.78, montos que representan el 61% y 79% del ingreso promedio de 
las familias. El 83% de los gastos médicos son causados por gasto en medicamentos. Las 
enfermedades que generaron mayores gastos médicos fueron LES ($7,339.44 promedio 
mensual), Dermatomiositis $4,800 y AR con $1,405.56 promedio mensual. Los gastos 
inesperados como intervenciones quirúrgicas causadas por la enfermedad $9,000 pro-
medio y las hospitalizaciones por complicaciones $8,500. El costo anual del tratamiento 
con rituximab asciende a $117,66.60 monto que representa el 167% del ingreso de las 
familias. ConClusiones: El costo de las enfermedades reumatológicas genera una 
carga financiera importante, los pacientes diagnosticados por una causa reumatológica 
ven mermada su situación financiera, es decir, incurren en gastos catastróficos en salud. 
El uso de tratamientos biológicos sobrepasa los ingresos anuales de las familias.
PSY7
análiSiS ecOnOmicO De la PrOfilaxiS SecunDaria verSuS el 
tratamientO a DemanDa De una cOhOrte De PacienteS cOlOmbianOS 
cOn hemOfilia a Y b Severa
Ruiz A.F.1, Guarin N.E.2, Diaz J.A.3, Arevalo H.O.2, Portilla A.1, Machado J.E.1
1Audifarma, Bogotá, Colombia, 2Salud Total, Bogotá, Colombia, 3Facultad de Ciencias, Universidad 
Nacional de Colombia, Bogotá, Colombia
objeCtivos: Evaluar las diferencias en efectividad y costos de la pro-
filaxis secundaria vs el tratamiento a demanda en pacientes con hemofilia 
severa. MetodologíAs: Pacientes: Seguimiento retrospectivo durante 30 meses 
a una cohorte de 52 pacientes con diagnóstico confirmado de Hemofilia A y B severa, 
atendidos por una institución prestadora de servicios de alta complejidad a nivel 
nacional. La permanencia minina dentro de la cohorte fue de 12 meses. Perspectiva: 
Asegurador. Desenlaces en salud: promedio de sangrado articular/pacientes/mes. 
Costos: Se evaluaron los costos médicos directos (atención hospitalaria, atención 
ambulatoria, urgencias, medicamentos), tomados del sistema de información del 
asegurador y del prestador a precios de 2012, en COP. ResultAdos: Desenlaces en 
Salud: Los 52 pacientes aportaron 847 meses de tratamiento en demanda con 154 
sangrados y 539 meses en profilaxis con 93 sangrados. La tasa de sangrado paciente/
mes fue de 0,18 para demanda y de 0,17 para profilaxis (p= 0,627), con un RR de 
0,949 (IC95% 0,78 - 1,15). Costos: Si se toma en cuenta la administración de antin-
